Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial - Schwedt, Todd J.; Myers Oakes, Tina M.; Martinez, James M.; Vargas, Bert B.; Pandey, Hitendra; Pearlman, Eric M.; Richardson, Diane R.; Varnado, Oralee J.; Cobas Meyer, Michael; Goadsby, Peter J. (Neurology and therapy, 2024)
Keywords: Calcitonin gene-related peptide (CGRP); CGRP antagonist; Galcanezumab; Gepant; Head-to-head; Internal Medicine; Medicine; Medicine & Public Health; Migraine; NCT; NCT05127486; Neurology; Original Research; Prevention; Rimegepant; Comparative efficacy; Calcitonin gene-related peptide (CGRP); Migraine; CGRP antagonist; Head-to-head; Galcanezumab; Gepant; Clinical study